Virbac starts phased European launch of Floragest for dogs and cats

16/10/2026

Virbac has begun a phased European launch of Floragest, moving further into the everyday companion-animal digestive-care market with a product designed for dogs and cats. The September rollout is commercially notable because it sits at the junction of veterinary recommendation, home administration and the expanding interest in microbiome-focused pet care.

The company describes Floragest as a blend of prebiotics and postbiotics intended to support a healthy digestive ecosystem. Virbac says its prebiotics selectively nourish beneficial bacteria already present, while its postbiotics act directly on intestinal tissue to strengthen the protective barrier. The positioning reflects a care need that can arise around stress, dietary change or antibiotic treatment, all common points of conversation between practices and pet owners.

For a veterinary business, digestive support is not simply a one-off clinical event. It is an area where routine advice, nutritional management and product adherence can meet. Virbac has formulated Floragest as a daily, highly palatable soft chew, with one chew a day for cats and dogs. That format is aimed at reducing the administration friction that can limit consistent use of home-care products.

The company says the product is intended to support regulated digestion, firmer stools, reduced gas and the body's natural defences. Those are company-described benefits, not a substitute for diagnosis where an animal has persistent or serious signs. Yet the model is strategically relevant: a palatable home-care product can extend the veterinary relationship beyond the consultation room, provided the product is used appropriately and alongside clinical guidance where needed.

The phased, multi-country European rollout gives Virbac a route to build presence in a category that connects preventive care and daily owner behaviour. Its success will depend on execution across veterinary channels and on how clearly the microbiome proposition translates into practical outcomes owners can understand. The release shows a company seeking growth not through a dramatic therapeutic breakthrough, but through a repeatable, routine-care proposition with broad companion-animal reach.